Sign inJoin waitlistJoin the waitlist

Natalie Sinclair

Associate Medical Director, Dana-Farber Brigham Cancer Center · Mass General Brigham

Credentials: · · · · ·

History

Dana-Farber Brigham Cancer Center · Mass General Brigham
Present

Hematology and Medical Oncology
Brown University
2008–2011
Internal Medicine
University of Vermont Medical Center
2005–2008
Robert Larner College of Medicine
2001–2005

Research

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized…
JAMA Oncology · 2020 · 139 citations
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone…
Journal of Clinical Oncology · 2024 · 105 citations
Glycine-extended gastrin synergizes with gastrin 17 to stimulate acid secretion in gastrin-deficient mice
Gastroenterology · 2000 · 57 citations

Sara Tolaney
14 papers
Meredith Faggen
13 papers
Elizabeth Mittendorf
9 papers
Ann Partridge
7 papers
Eric Winer
7 papers
Adrienne Waks
6 papers
Erica Mayer
6 papers
Harold Burstein
6 papers
Michael Constantine
6 papers
Nadine Tung
6 papers
Nancy Lin
6 papers
SS
Sarah Sinclair
6 papers

Clinical trials

The Young Women's Breast Cancer Study
Principal investigator · Active not recruiting
Dana-Farber Cancer Institute
2006–2035
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Site PI · Recruiting · Phase 3
American Society of Clinical Oncology
2024–2028
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Site PI · Recruiting · Phase 2
Dana-Farber Cancer Institute
2021–2029